



LEO Pharma | ISAD 2021

Explore the ePoster:

# Efficacy and safety of tralokinumab in a Korean subpopulation of patients with moderate-to-severe atopic dermatitis: a subanalysis of ECZTRA 2, a Phase 3, monotherapy, randomized, double-blind, placebo-controlled trial

Kyu Han Kim, Sang Wook Son, Yang Won Lee, Eric L Simpson, Alexandra Kuznetsova, Sang Hyun Cho

**Dermatology  
beyond the skin**



Tralokinumab is an investigational compound. The safety and efficacy of tralokinumab has not been established by any regulatory authority yet.

MAT-44274

March 2021

ALL LEO TRADEMARKS BELONG TO THE LEO GROUP

© LEO Pharma A/S

LEO Pharma A/S, Industriparken 55,

DK-2750, Ballerup, Denmark